Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsule and soft gelatin capsules. Marksans Pharma offers products in the therapy areas of antibiotics, antidiabetic, anti-inflammatory, cardiovascular, gynaecology and pain management among others. The company’s research and development capabilities include dossier development, process optimization, chemical synthesis, formulation development, analytical development, and conducting stability studies. It operates sophisticated manufacturing plant in Goa. It markets products through a network of distributors in the US, the UK, Australia, New Zealand and Canada, among others. Marksans Pharma is headquartered in Mumbai, Maharashtra, India.
Marksans Pharma Ltd (MARKSANS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Marksans Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Marksans Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Marksans Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Marksans Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Marksans Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marksans Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Breckenridge Pharma Enters Into Co-Marketing Agreement With Marksans Pharma For Gabapentin Capsules 11
Equity Offering 12
Marksans Pharma Raises USD21 Million in Private Placement of Shares 12
Marksans Pharma Acquires Time-Cap Lab 13
Marksans Pharma Ltd - Key Competitors 14
Marksans Pharma Ltd - Key Employees 15
Marksans Pharma Ltd - Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Recent Developments 18
Financial Announcements 18
May 29, 2017: Marksans Pharma Announces Results for Fourth Quarter and Year Ended march 31,2017 18
Feb 06, 2017: Marksans Pharma Reports Financial Results For Quarter Ended December 31, 2016 20
Corporate Communications 21
Mar 14, 2018: Appointment of Mr. Digant Mahesh Parikh as Independent Director 21
Legal and Regulatory 22
Oct 09, 2017: Marksans Pharma: Receipt of Establishment Inspection Report (EIR) from the US FDA 22
Feb 20, 2017: Marksans Pharma Announces Inspection of Goa Plant by UK MHRA 23
About GlobalData 24
Contact Us 24